Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
N/A
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 1(2)
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05016427Phase 1Unknown

A Study of Possibility of Using Regulatory T Cells(VT301) for Treatment of Alzheimer's Disease

Role: lead

NCT03865017Phase 1Unknown

A Safety and Tolerability Study of GB301

Role: lead

NCT03973099Not ApplicableCompleted

Double Blinded, Randomized, Placebo-controlled Clinical Study for Nelumbinis Semen

Role: lead

NCT01715350Phase 2Completed

Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease

Role: lead

All 4 trials loaded